NOVARTIS

NOVARTIS logo
πŸ‡¨πŸ‡­Switzerland
Ownership
Public, Private
Established
1996-01-01
Employees
76K
Market Cap
$242.6B
Website
https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough

First Posted Date
2015-03-05
Last Posted Date
2016-07-11
Lead Sponsor
Novartis
Target Recruit Count
70
Registration Number
NCT02379637

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

First Posted Date
2014-12-02
Last Posted Date
2016-01-05
Lead Sponsor
Novartis
Target Recruit Count
55
Registration Number
NCT02305446
Locations
πŸ‡΅πŸ‡±

01, Novartis Investigational Site, Krakow, Poland

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries

First Posted Date
2014-11-14
Last Posted Date
2017-04-19
Lead Sponsor
Novartis
Target Recruit Count
215
Registration Number
NCT02290821
Locations
πŸ‡ΊπŸ‡Έ

US Site, Houston, Texas, United States

A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-10-22
Last Posted Date
2016-04-05
Lead Sponsor
Novartis
Target Recruit Count
102
Registration Number
NCT02271854
Locations
πŸ‡ΊπŸ‡Έ

Lotus Clinical Research, 100 W California Blvd,, Pasadena,, California, United States

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2014-09-10
Last Posted Date
2016-05-04
Lead Sponsor
Novartis
Target Recruit Count
1
Registration Number
NCT02235740
Locations
πŸ‡ΊπŸ‡Έ

Novartis Investigative Site, Cary, North Carolina, United States

Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects β‰₯ 1 Years of Age

First Posted Date
2014-06-27
Last Posted Date
2017-04-07
Lead Sponsor
Novartis
Target Recruit Count
885
Registration Number
NCT02177032
Locations
πŸ‡΅πŸ‡­

1, Research Institute for Tropical Medicine, Muntinlupa, Philippines

πŸ‡΅πŸ‡­

2, Asian Hospital and Medical Center, Muntinlupa, Philippines

πŸ‡΅πŸ‡­

4, De La Salle Health Sciences Institute, Cavite, Philippines

and more 3 locations

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-05-19
Last Posted Date
2017-02-15
Lead Sponsor
Novartis
Target Recruit Count
239
Registration Number
NCT02141516
Locations
πŸ‡΅πŸ‡±

31, Novartis Investigational Site, Krakow, Poland

πŸ‡΅πŸ‡±

33, Novartis Investigational Site, Warszawa, Poland

πŸ‡΅πŸ‡±

30, Novartis Investigational Site, Wroclaw, Poland

and more 17 locations

Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days

First Posted Date
2014-03-28
Last Posted Date
2014-07-24
Lead Sponsor
Novartis
Registration Number
NCT02099149
Locations
πŸ‡ΏπŸ‡¦

Respiratory and Meningeal Pathogen Research Unit, Soweto, Gauteng, South Africa

Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine

First Posted Date
2013-10-31
Last Posted Date
2015-06-11
Lead Sponsor
Novartis
Target Recruit Count
900
Registration Number
NCT01973205

Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)

First Posted Date
2013-10-23
Last Posted Date
2015-06-03
Lead Sponsor
Novartis
Target Recruit Count
304
Registration Number
NCT01967550
Β© Copyright 2024. All Rights Reserved by MedPath